Phosphorex, NOF Corporation, NeoSome Life Sciences, NIS, and Envol Biomedical Form the LNP Alliance

Phosphorex, NOF Corporation, NeoSome Life Sciences, NanoImaging Services (NIS), and Envol Biomedical have joined forces to establish the LNP Alliance, a strategic partnership dedicated to advancing lipid nanoparticle (LNP) technology and accelerating the development of next-generation therapeutics.

The LNP Alliance brings together scientific expertise, proprietary lipid innovations, formulation capabilities and analytical and drug efficacy services to support biopharma and biotech companies in overcoming drug development challenges. By combining forces, the LNP Alliance aims to provide a comprehensive, end-to-end solution encompassing lipid synthesis, formulation development, process optimization, analytical characterization, and manufacturing support—enabling partners to efficiently move from discovery to clinical success.

The LNP Alliance offers:

• Access to proprietary ionizable lipids and excipients for optimized drug delivery
• Expert formulation and process development to enhance LNP stability and efficacy
• Integrated analytical and manufacturing capabilities for streamlined scale-up
• Cryo-TEM imaging for nanoparticle characterization
• Biodistribution, efficacy, and toxicology evaluations in multiple animal models, including Non-Human Primates

“The LNP Alliance represents a unique convergence of industry leaders, each bringing specialized expertise to drive innovation in LNP-based drug development,” said Jarlath Keating, CEO of Phosphorex. “By working together, we provide a comprehensive solution that allows our partners to develop more effective therapies, faster.”